The Galien Foundation Debuts 2017 Prix Galien USA Nominees in "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Medical Technology" Categories

NEW YORK, July 26, 2017 /PRNewswire/ -- The Galien Foundation announced today the 2017 11^th Annual Prix Galien USA Award Nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and technology product achievement that improves the human condition.

To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for market within the last five years and demonstrate tremendous potential to impact human health. Sales data are not considered by the nominating committee in their award nominee selection; only science and health impact.

"The 2017 nominees are working each day to ensure a healthier future for the next generation," said Dr. P. Roy Vagelos, chairman, Prix Galien USA Awards Committee, and prior recipient of the Pro Bono Humanum Award. "The selection committee appreciates the unwavering devotion by the teams of researchers, scientists and innovators that have dedicated their lives to such a worthy cause, and we are honored to recognize their achievements."

The Prix Galien USA 2017 nominees include in-market products evaluated in the following categories: "Best Biotechnology Product" – 15 nominees; "Best Pharmaceutical Agent" – 34 nominees, and "Best Medical Technology" – 11 nominees.

Best Biotechnology Product (Nominees)

Best Pharmaceutical Agent (Nominees)

Best Medical Technology (Nominees)

"As the realm of scientific discovery and medical innovation shuttles forward, we were thrilled to see so many high-caliber submissions this year," said Bruno Cohen, chairman of the Galien Foundation.  "Our Foundation is continually impressed by the achievement of the Prix Galien candidates each year, but 2017 has become a benchmark for future years."

The Prix Galien USA Committee is comprised of thirteen renowned leaders from the biomedical industry and academia, including four Nobel Laureates, responsible for evaluating nominees. Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2017, at the American Museum of Natural History in New York City.  Registration to attend the 2017 Prix Galien USA Awards Ceremony can be accessed here.

Prix Galien Awards Committee 2017

Pr Richard AXEL,
M.D. Nobel Laureate, Co-director, the Kavli Institute for Brain Science, Columbia University Medical Center, New York

Pr Michael S. BROWN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Susan DESMOND-HELLMANN,
M.D., M.Ph. Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA

Pr Laurie GLIMCHER,
M.D. Chief Executive Officer and President, Dana Farber Cancer Institute, Professor of Medicine, Harvard Medical School

Pr Joseph GOLDSTEIN,
M.D. Nobel Laureate, Professor of Molecular Genetics and Internal Medicine, UT, Southwestern Medical Center, Dallas, TX

Pr Robert S. LANGER,
M.D. David H. Koch Institute Professor at MIT

Pr Cato T. LAURENCIN,
M.D., Ph.D. University Professor, University of Connecticut, CT

Pr Paul A. MARKS,
M.D. Laboratory Head of Cell Biology Memorial Sloan Kettering Cancer Center, New-York. President Emeritus, MSKCC

Pr Rebecca RICHARDS-KORTUM,
Ph.D. Professor of Bioengineering, Malcolm Gillis University, Houston, TX

Pr Michael ROSENBLATT,
M.D. Chief Medical Officer of Flagship Ventures, Cambridge, MA

Pr Bengt SAMUELSSON, M.D., Ph.D. Nobel Laureate, Former President of Karolinska Institute and Former Chairman of the Nobel Foundation

Pr Marc TESSIER-LAVIGNE,
Ph.D. President, Stanford University, Stanford, CA

Pr P. Roy VAGELOS,
M.D. Retired Chairman and CEO, Merck & Co., Inc. Chairman of the Board, Regeneron Pharmaceuticals, Inc. Committee Chairman

About The Galien Foundation

The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.

For more information, visit www.galienfoundation.org.

Galien Foundation Media Contact:
Giana Gregga
Finn Partners
312-329-3910
[email protected]

SOURCE The Galien Foundation

Related Links

http://www.galienfoundation.org